Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kivu Bioscience, Sterling Pharma Solutions Enter Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Kivu Bioscience, Sterling Pharma Solutions Enter Manufacturing Pact

Sterling will manufacture cGMP clinical material for KIVU-107 at its bioconjugation facility in Deeside, UK.

Kivu Bioscience, a biotech company developing next-gen antibody-drug conjugates (ADCs), entered a manufacturing agreement with Sterling Pharma Solutions, a global CDMO, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology ADC candidate, KIVU-107.

Sterling will manufacture cGMP clinical material for KIVU-107 at its dedicated bioconjugation facility in Deeside, UK. The collaboration includes process familiarization, analytical development, process optimization, and scale-up activities in preparation for a cGMP manufacturing campaign.

KIVU-107 is a potential first-in-class antibody-targeted conjugate which enables site-specific conjugation. The resulting structure positions the linker-payload in a natural cavity in the antibody, providing excellent stability, reduced hydrophobicity, and an increased therapeutic index relative to first-generation ADC therapies.

“We chose Sterling as our manufacturing partner based on their deep expertise in ADC development, proven track record of clinical supply, and commitment to quality,” said Mohit Trikha, Ph.D., President and Chief Operating Officer, Kivu Bioscience. “This partnership marks an important milestone as we advance KIVU-107 toward first-in-human studies and deliver on our mission to bring kinder, gentler and efficacious next-generation ADC therapies to patients.”

Sterling’s 6,500-square-meter Deeside facility offers a range of ADC services, from discovery-stage development through to clinical supply. In October 2024, Sterling announced a £10 million investment at the site to double its GMP manufacturing capacity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics